Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-CVOT: tirzepatide versus dulaglutide for major cardiovascular events in type 2 diabetes
2023-507846-96-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 30
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Tirzepatide with Dulaglutide (2 arms). Primary endpoints: Time to first occurrence of death from cardiovascular causes, myocardial infarction, or stroke (MACE-3) and Time to first occurrence of a component event of MACE-3. Planned start Jun 2020; status: authorised.
02
Drugs
tirzepatidedulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-507846-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507846-96-00.